1 citations,
March 2018 in “Dermatologie pro praxi” Most over-the-counter hair loss treatments lack strong evidence of effectiveness, except for minoxidil, which works but stops working if you stop using it.
March 2024 in “Clinical, cosmetic and investigational dermatology” Severe alopecia areata greatly impacts quality of life, mental health, and daily activities.
December 2023 in “Dermatology and therapy” Japanese patients and physicians often disagree on the severity of Alopecia Areata and treatment satisfaction, needing better communication and treatments.
There are many treatments for common hair loss, but more trials are needed to decide which are best.
November 2021 in “Research, Society and Development” Individualized treatment and psychological support are crucial for alopecia.
January 2019 in “Elsevier eBooks” Different hair disorders have specific treatments and outcomes, with some resolving on their own and others requiring medication or emotional support.
OCT can effectively screen and diagnose various medical conditions non-invasively.
January 2018 in “Przegla̧d dermatologiczny” The Polish Dermatological Society recommends personalized treatment for cutaneous lupus, including lifestyle changes, medications, and monitoring, with specific drugs for severe cases.
June 2017 in “Poster presentations” All four treatments for early rheumatoid arthritis had similar safety profiles.
January 2015 in “Prace Naukowe Uniwersytetu Ekonomicznego we Wrocławiu” Using Lasswell's model can make CSR communication more effective and trusted.
September 2010 in “Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii” TrichoScan is reliable for counting and measuring hair density but may not accurately assess hair types in women with hair loss.
2 citations,
May 2022 in “The journal of immunology/The Journal of immunology” BST2 protein and certain T cells increase in early alopecia areata.
1 citations,
August 2022 in “JAAD Case Reports” A woman's complete hair loss condition improved after recovering from COVID-19.
1 citations,
January 2023 in “IDCases” A patient experienced severe hair loss after getting an mRNA COVID-19 vaccine.
1 citations,
September 2022 in “BioNanoScience” Tofacitinib can help hair grow back in alopecia patients but hair loss might return if the dose is lowered.
ILC1-like cells can independently cause alopecia areata by affecting hair follicles.
37 citations,
December 2017 in “Journal of Investigative Dermatology Symposium Proceedings” Black and Hispanic women are more likely to have alopecia areata than white women.
2 citations,
July 2023 in “Journal of dermatology” Alopecia areata causes a significant economic burden in Japan, mainly due to productivity loss.
September 2024 in “Skin Appendage Disorders” Tofacitinib helped a woman regrow her hair without relapses after other treatments failed.
February 2024 in “Actas dermo-sifiliográficas/Actas dermo-sifiliográficas” Most alopecia areata patients in the study were women, aged 15-49, with patchy hair loss and often had other health conditions.
October 2023 in “The Cochrane library” The medicine baricitinib was found to notably improve hair regrowth in alopecia areata, but more research is needed on its side effects and other treatments.
September 2023 in “British Journal of Dermatology” Hair regrowth from severe alopecia areata treatment with baricitinib can vary, with faster results in those with shorter hair loss duration.
April 2017 in “Al-Azhar Medical Journal” PRP is an effective and safe treatment for alopecia areata.
130 citations,
February 2019 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” JAK inhibitors are effective for treating alopecia areata, with most patients seeing hair growth after treatment.
56 citations,
January 2019 in “Lancet” JAK inhibitors help regrow hair in alopecia areata patients, improving their quality of life.
45 citations,
November 2018 in “Journal of dermatological treatment” JAK-inhibitors are effective for treating psoriasis and show promise for other skin diseases.
4 citations,
January 2020 in “PubMed” JAK inhibitors may become the first approved treatment for alopecia areata if they are proven safe and effective.
3 citations,
April 2016 in “Journal of Investigative Dermatology” Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.
2 citations,
April 2017 in “Journal of Investigative Dermatology” Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.
1 citations,
January 2020 in “Surgical & Cosmetic Dermatology” Combining oral minoxidil with JAK inhibitors helps regrow hair in severe alopecia areata cases.